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Objective: To examine the impact of type 2 diabetes
on direct and indirect costs and to describe the effect
of relevant diabetes-related factors, such as type of
treatment or glycaemic control on direct costs.
Design: Bottom-up excess cost analysis from a
societal perspective based on population-based survey
data.
Participants: 9160 observations from 6803
individuals aged 31–96 years (9.6% with type 2
diabetes) from the population-based KORA
(Cooperative Health Research in the Region of
Augsburg) studies in Southern Germany.
Outcome measures: Healthcare usage, productivity
losses, and resulting direct and indirect costs.
Methods: Information on diabetes status, biomedical/
sociodemographic variables, medical history and on
healthcare usage and productivity losses was assessed
in standardised interviews and examinations.
Healthcare usage and productivity losses were costed
with reference to unit prices and excess costs of type 2
diabetes were calculated using generalised linear
models.
Results: Individuals with type 2 diabetes had 1.81
(95% CI 1.56 to 2.11) times higher direct (€3352 vs
€1849) and 2.07 (1.51 to 2.84) times higher indirect
(€4103 vs €1981) annual costs than those without
diabetes. Cardiovascular complications, a long diabetes
duration and treatment with insulin were significantly
associated with increased direct costs; however,
glycaemic control was only weakly insignificantly
associated with costs.
Conclusions: This study illustrates the substantial
direct and indirect societal cost burden of type 2
diabetes in Germany. Strong effort is needed to
optimise care to avoid progression of the disease and
costly complications.
BACKGROUND
Diabetes mellitus is one of the most common
chronic diseases worldwide and its preva-
lence continues to increase. The sixth
edition of the International Diabetes
Federation (IDF) World Diabetes Atlas
indicates that the current number of diag-
nosed and undiagnosed patients will rise
from 382 million currently to around 592
million in 2035.1 In 2010, the prevalence of
known type 2 diabetes in the German popu-
lation aged 20–79 was 7–8% and this number
is expected to increase over the next
decades.2–4
Previous German and international studies
have shown that diabetes is associated with a
higher usage of medical services and incap-
acity to work,5 6 resulting in significantly
higher direct and indirect societal costs.7–16
For example, a study based on administrative
health claims data (AOK/KV Hesse) showed
that the excess direct medical costs of
diabetes mellitus in 2009 averaged €21
billion in Germany.17 Studies from the USA
and England reported annual direct medical
costs of $176 billion and £10 billion,
respectively.18 19
As one of the leading causes of morbidity
and mortality, diabetes leads to a broad
range of microvascular and macrovascular
complications, such as retinopathy, nephro-
pathy, neuropathy, stroke and myocardial
infarction.20–23 It is known that a large part
of the excess costs of diabetes is attributable
to these diabetes-related complications and
Strengths and limitations of this study
▪ Population-based data source with more than
9000 observations.
▪ Detailed information about sociodemographic
(education) and clinical (diabetes duration, gly-
caemic control) factors that are not included in
(German) health insurance claims data.
▪ Analysis of direct and indirect cost components.
▪ Data are from regional studies and are not repre-
sentative of the rest of Germany.
▪ Information on healthcare usage is based on
self-reports and individual costs are approxi-
mated using standardised unit costs.
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that immediate costs for the disease management repre-
sent only a small share of costs.20 21 24
Most previous German cost-of-illness studies on dia-
betes were based on routine data.5 7 24 25 However, these
studies were not able to differentiate between patients
with type 1 or 2 diabetes or to control for important
confounders like educational status. Furthermore, claims
data from health insurances do not cover information
on factors like diabetes duration or glycaemic control.7
Population-based surveys often comprise less detailed
information on healthcare usage, but they provide
precise information on disease-related factors.
The objective of this study is to use data from
population-based surveys to examine the impact of dia-
betes on direct and indirect costs from a societal per-
spective and to analyse important factors, such as
glycaemic control and diabetes duration, that cannot be
analysed in German insurance claims data.
RESEARCH DESIGN AND METHODS
Data and study design
We used pooled data from five KORA (Cooperative
Health Research in the Region of Augsburg) surveys, F3
(2004/2005, n=3184), F4 (2006/2008, n=3080), Age1
(2008/2009, n=1079), Age2 (2012, n=822) and F4-L
(2010, n=1051), which were follow-up studies of four
baseline studies performed between the years 1984 and
2001 (figure 1). KORA is a regional research platform in
Southern Germany conducting population-based surveys
which focus on epidemiology and health economic
research aiming to study population health. Study
design, examination procedures and questionnaires of
the KORA surveys were very similar and allowed data
from these five surveys to be pooled. Detailed information
on the study design and methods have been described
elsewhere.26 27 In total, data on 6844 participants were
available. Of those, 4869 participants participated in one
survey, 1578 participants in two surveys and 397 partici-
pants in three surveys, adding up to 9216 observations.
Participants reported information on sociodemo-
graphic variables, risk factors, their medical history,
medication and healthcare usage. Biomedical variables,
such as glycated haemoglobin (HbA1c), were collected
during standardised examinations at the KORA study
centre.
Variables were assessed and defined as follows:
Diabetes status: For the majority of observations, vali-
dated information on the status and type of diabetes was
available from the participants’ general practitioners
(GPs). Since both sensitivity (94%) and specificity
(98%) of self-reported diabetes status were high, self-
reports were used in case no validated information on
the diabetes status was available. In this case, it was
assumed that patients had type 2 diabetes if onset was
after 40 years of age. Participants without information
on their diabetes status were excluded from the analysis.
Diabetes-related factors: Self-reported information on dur-
ation of the disease, type of therapy (insulin, oral anti-
diabetic drugs, insulin combined with oral antidiabetic
drugs, without any medical treatment) and macrovascu-
lar comorbidities (stroke, myocardial infarction) was
assessed in standardised interviews or questionnaires.
Glycaemic control in patients with diabetes was defined by
HbA1c (categorised as HbA1c<6.5%, 6.5%≤HbA1c<7.5%,
7.5%≤HbA1c<9.0%, HbA1c≥9.0%).
Covariates: Information on age (defined in 10-year age
groups), sex and education (‘basic education’, ie,
Figure 1 Data source: 4869
participants participated in one,
1578 participants in two and 397
participants in three of the
population-based KORA
(Cooperative Health Research in
the Region of Augsburg) surveys
summing up to 6844 participants
and 9216 observations.
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≤9 years of schooling, ‘medium education’ and ‘higher
education’, ie, ≥12 years of schooling) was assessed in
standardised interviews or questionnaires.
Usage of medical services and cost analysis
Direct costs
The calculation of direct costs included outpatient ser-
vices, hospital care, rehabilitation and medication. By
multiplying individual resource usage per year with unit
costs, annual costs per observation were generated.
Resource usage regarding outpatient physician visits,
inpatient and outpatient hospital treatments and rehabi-
litations were assessed for a specific time period. The
time horizons varied from 7 days for medication,
3 months for outpatient physician contacts and
12 months for inpatient and outpatient stays hospital
and rehabilitation. We extrapolated all measures to
12 months, under the assumption that the data were rep-
resentative of the entire year. Medical services, including
contact with outpatient physicians, as well as inpatient
and outpatient rehabilitation and hospital stays were
valued by unit costs as provided by Bock et al.28 Unit
costs for a specialist visit ranged between €18.89 for a
dermatologist and €78.08 for a psychotherapist visit. An
overview of the different unit costs is given in online
supplementary appendix 1.
To reduce the degree of complexity and to allow
easy interpretation of the data, after detailed costing, the
cost of outpatient services was summarised in three
groups: GPs (GPs and internists working as primary care
providers), internists (internists, internal specialists,
cardiologists and pulmonologists) and other physicians
(gynaecologists, surgeons, orthopaedists, urologists,
ophthalmologists, dermatologists, neurologists, psy-
chotherapists, psychiatrists, occupational health practi-
tioners, radiologists and other doctors).
The reason for hospitalisation was not documented
and hospitalisations were costed according to the price
given by Bock et al of €593.04 per inpatient day. Since
no standard price for outpatient hospital visits is avail-
able, we applied the standard price of the category
‘other outpatient doctors’ of €40.06. Inpatient and out-
patient rehabilitation was priced at €121.85 and €46.68
per day, respectively.28
Pharmaceutical expenditures were calculated from
information on name, pharmaceutical identification
number and dosage of drug intake during the previous
7 days. If pharmaceuticals were taken irregularly, the
intake per week was assumed by using the defined daily
dose (DDD). The cost of medication was estimated
using the pharmacy retail prices from the Scientific
Institute of the AOK healthcare insurance (WIdO) and
the price index calculator of the Federal Statistical
Office.29 30 Weekly costs were then extrapolated to
1 year. Details on the assessment of drug usage have
been described elsewhere.31 Neither mandatory manu-
facturer discounts nor over-the-counter medications
were taken into account. All prices were adjusted to the
year 2011.
Indirect costs
According to the Institute for Quality and Efficiency in
Health Care (IQWIG), indirect costs are caused due to
losses in productivity such as sick days, long-term incap-
acity to work or premature death.32 To determine indir-
ect costs, two alternative valuation methods are known,
both of which represent the societal perspective. The
human capital approach focuses on loss of productivity.
Average labour costs are an approximation for loss of
productivity. In contrast, according to the friction cost
method, indirect costs only occur until a replacement
has been found. For the friction cost method, it has been
suggested that the costs of productivity loss constitute
80% of labour costs.32 33 We used the human capital
approach in our main analysis and applied the friction
cost method in a sensitivity analysis. Annual average
labour costs per employee in 2011 (€36 103) were
assessed from reports of the Federal Statistical Office.34
The regular retirement age in Germany is 65 years. In
the survey, only participants younger than 65 years were
asked about their productivity losses and analyses of indir-
ect costs are therefore restricted to this age group.
In the surveys, participants were asked about their
number of sick leave days in the previous 12 months and
if they receive incapacity benefits. To calculate the costs
resulting from sick leave, the number of sick leave days
was multiplied by the average labour cost per employee
and day in 2011. Average labour costs per day (€170.86)
were derived by dividing the number of effective
working days (211.3 days) by the average annual labour
costs (€36 103).35
To assess the societal costs of long-term incapacity of
work, annual labour costs (€36 103) were assigned to par-
ticipants who stated receiving incapacity benefits. 50% of
annual labour costs (€18,051.50) were assigned to partici-
pants who stated receiving incapacity benefits and
working part-time. Costs of participants with implausible
information, for example, indicating full-time work and
receiving incapacity benefits, were set to zero.
We did not consider costs due to unpaid work, pres-
entism or premature death.
Missing information in single studies
In the Age2 survey, only the cumulative number of spe-
cialist visits was reported, but not the number of visits to
each specialist out of the list of 20 different outpatient
specialists. All participants of the Age2 survey (2012)
also participated in the Age1 survey (2008/2009), in
which the cumulative number of visits to all specialists
and the number of visits to the 20 different specialist
groups were available. Therefore, the number of visits to
the 20 specialist groups in Age2 was estimated assuming
the same distribution as in Age1.
Both the Age1 and Age2 surveys were lacking informa-
tion about outpatient hospital visits and inpatient and
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outpatient rehabilitation. We therefore imputed the
mean values of individuals with the same age range in
the F3 and F4 surveys. Finally, missing information on
incapacity benefits in the F4-L survey (2011) was trans-
ferred from F4 (2008), as all participants in the F4-L
survey were also part of the F4 survey. The plausibility of
information on health service usage was checked thor-
oughly. Individuals with implausible answers (eg, 416
doctor visits per year, n=5), one individual with
extremely high medication costs of €200 000, as well as
individuals with missing information on diabetes status
or covariates (n=50) were excluded from the analysis,
resulting in a final analysis sample of 9160 observations
from 6803 participants.
Statistical analysis
In a first step, we estimated the odds of having any
healthcare usage depending on the diabetes status by
applying a generalised estimating equation (GEE) with a
binary distribution and a logit link. In the next step, we
estimated the impact of diabetes on the frequency of
healthcare usage and the number of sick leave days for
participants with at least one healthcare contact or sick
leave day, using a GEE with a γ distribution and a log
link. Model assumptions and choice of distribution/
family link were guided by the underlying right-skewed
distribution and non-negative value range of the
outcome variables.
Diabetes-related costs were calculated using an excess
cost approach stratified for direct and indirect cost com-
ponents. Since cost variables also follow a right-skewed dis-
tribution with many participants having non-negative low
costs and a few having high costs, a model with a γ distri-
bution and a log link was used and a hypothetical value of
€1 was assigned for observations with zero costs. The
β-coefficients were exponentiated to provide the cost ratio
between individuals with and without type 2 diabetes.
Following these main analyses, we examined the
impact of disease severity and type of treatment on
direct medical costs. All models were adjusted for age,
sex and education and an exchangeable covariance
structure was assumed for the GEEs. To assess to which
degree excess diabetes costs are attributable to weight
status, a factor that often precedes type 2 diabetes, add-
itional models were adjusted for BMI. Statistical analyses
were performed using SAS software V.9.2 (SAS Institute,
Cary, North Carolina, USA).
RESULTS
Sample characteristics
Table 1 describes the sociodemographic characteristics
of the study sample. Of the 9160 observations, a








Male (%) 476 (54.1%) 3980 (48.1%) 4456 (48.7%)
Age, mean [SD] 71.0 [10.0] 59.6 [14.1] 60.7 [14.2]
Education level
Basic education 658 (74.8%) 4596 (55.5%) 5254 (57.4%)
Medium education 130 (14.8%) 1920 (23.2%) 2050 (22.4%)
Higher education 92 (10.5%) 1764 (21.3%) 1856 (20.3%)
BMI, mean [SD] 31.0 [5.1] 27.4 [4.5] 27.8 [4.7]
Myocardial infarction 138 (15.8%) 364 (4.4%) 502 (5.5%)
Stroke 92 (10.5%) 285 (3.5%) 377 (4.1%)






No treatment 87 (11.1%)
Nutritional 76 (9.7%)
Oral antidiabetics 447 (57.2%)







Sample comprises 9160 observations from 6803 participants.
BMI, body mass index; HbA1c, glycated haemoglobin.
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diagnosis of type 2 diabetes was reported for 9.6%
(n=880). Cases with diabetes were on average 10 years
older, had a higher BMI and suffered more often from
cardiovascular disease than those without diabetes.
Diabetes was further associated with higher age and
lower education level.
Likelihood of healthcare usage, sick leave days and
long-term incapacity to work
In table 2, the odds of having any healthcare usage,
having any sick leave days or receiving incapacity bene-
fits are provided. Cases with type 2 diabetes were more
likely to have at least a physician visit (OR=2.04 (1.70 to
2.44)), an inpatient hospital treatment (OR=1.47 (1.24
to 1.75)) or an inpatient rehabilitation (OR=2.50 (1.79
to 3.50)) and to receive incapacity benefits (1.93 (1.31
to 2.83)) than those without type 2 diabetes. In particu-
lar, the odds of receiving any medication were signifi-
cantly increased (OR=4.86 (3.66 to 6.45)). No
significant effect was observed for outpatient hospital
treatment and outpatient rehabilitation.
Frequency of healthcare usage and number of sick leave
days given positive values
Table 3 summarises the effect of the diabetes status on
the frequency of healthcare use and the length of
absences from work due to illness, given that participants
had any healthcare usage or sick leave days. Among par-
ticipants with a physician visit, participants with diabetes
had a 24% (1.14% to 1.36%) higher number of visits
than those without diabetes (17 vs 14 visits in the past
12 months). Among participants with an inpatient hos-
pital treatment, patients with diabetes had 30% (1.07%
to 1.59%) longer hospital stays than those without
diabetes (15 vs 11 days in the past 12 months). Further,
among participants with at least one sick leave day,
the number of sick leave days in individuals with
diabetes was 2.40 (1.52 to 3.81) times higher than in
individuals without diabetes (35 vs 12 days in the past
12 months).
Excess direct and indirect costs
In table 4, the results of the regression analysis for costs
are provided. It illustrates that individuals with diabetes
had 1.81 (1.56 to 2.11) times higher direct (€3352 vs
€1849) costs and 2.07 (1.51 to 2.84) times higher indi-
rect (€4103 vs €1981) costs compared with individuals
without diabetes. Components with the highest absolute
contribution for direct costs were inpatient hospital
treatments (cost ratio=1.82; €1664 vs €917) and medica-
tion (cost ratio=2.01; €960 vs €478). Two-third of indirect
costs were attributable to sick leave days (cost ratio=2.57;
€3344 vs €1299). Adjusting the models additionally for
BMI attenuated the cost ratios for direct costs (from
1.81 to 1.67) and indirect costs (2.07 to 1.97) only mar-
ginally (results not shown in tables).
Excess costs related to treatment or severity of diabetes
Table 5 illustrates the excess direct costs of factors
related to the treatment or severity of diabetes. Patients
with diabetes and with cardiovascular comorbidities had
2.77 (2.12 to 3.61) times higher and patients with dia-
betes and without cardiovascular comorbidities had 1.54
(1.30 to 1.82) times higher direct costs than individuals
without diabetes. Moreover, type of treatment is strongly
associated with costs. Patients with diabetes treated with
oral antidiabetics had around 1.53 (1.25 to 1.88) times
higher direct costs and patients with diabetes treated
Table 2 Likelihood of having any healthcare usage or loss of productivity
Type 2 diabetes
Proportion (yes) OR (95% CI) No diabetes (reference)
Physicians’ visits
GPs 62.1% 2.04* (1.70 to 2.44) ref
Specialists 19.3% 1.44* (1.24 to 1.68) ref
Others 55.4% 1.76* (1.50 to 2.06) ref
Total 72.0% 2.48* (2.01 to 3.06) ref
Hospital treatment
Inpatient 15.6% 1.47* (1.24 to 1.75) ref
Outpatient† 27.8% 0.93 (0.69 to 1.26) ref
Rehabilitation
Inpatient† 23.4% 2.50* (1.79 to 3.50) ref
Outpatient† 22.1% 0.47 (0.19 to 1.18) ref
Medication 64.3% 4.86* (3.66 to 6.45) ref
Inability to work‡ (sick leave days) 49.4% 1.15 (0.73 to 1.82) ref
Early retirement§ 3.7% 1.93* (1.31 to 2.83) ref
GEE models with a binary distribution and a log link based on 9160 observations from 6803 participants.
Models are adjusted for age, sex and educational level and accounted for the repeated measurement structure.
*Significant at the level of 1%.
†In total,1909 observations were omitted in the model due to missing information in Age1, Age2.
‡Only for observations <65 years with a regular job (n=3637 observations).
§Only for observations <65 years (n=5207 observations).
GP, general practitioner.
Ulrich S, et al. BMJ Open 2016;6:e012527. doi:10.1136/bmjopen-2016-012527 5
Open Access









pen: first published as 10.1136/bm






with insulin had 3.98 (2.74 to 5.77) times higher direct
costs, compared with individuals without diabetes. Also,
the diabetes duration was associated with costs.
Individuals with a diabetes duration of more than
20 years had 50–100% higher costs than individuals with
a diabetes duration of <10 years. Glycaemic control was
only weakly associated with direct medical costs. After
mutual adjustment for cardiovascular complications, gly-
caemic control, type of treatment and diabetes duration,
only the factors cardiovascular complications and type of
treatment were significantly associated with direct costs.
Estimates on factors affecting healthcare costs of patients
with diabetes from a mutually adjusted model are illu-
strated in online supplementary appendix 2.
Table 3 Frequencies of healthcare usage and number of sick leave days—only considering observations with healthcare
use or sick leave days
Type 2 diabetes No diabetes
Ratio* (95% CI) Adjusted means (95% CI) Adjusted means (95% CI)
Number of physicians’ visits
GPs 1.29† (1.17 to 1.41) 9.44 (8.65 to 10.31) 7.35 (7.08 to 7.63)
Specialists 1.45† (1.12 to 1.89) 5.08 (3.99 to 6.48) 3.50 (3.18 to 3.84)
Others 1.06 (0.94 to 1.18) 9.28 (8.32 to 10.34) 8.78 (8.47 to 9.1)
Total 1.24† (1.14 to 1.36) 17.30 (15.91 to 18.8) 13.92 (13.5 to 14.36)
Number of hospital days
Inpatient 1.30† (1.07 to 1.59) 14.76 (11.8 to 18.46) 11.20 (10.22 to 12.27)
Outpatient‡ 0.86 (0.60 to 1.24) 4.69 (3.38 to 6.49) 5.44 (4.69 to 6.32)
Number of rehabilitation days
Inpatient‡ 0.88† (0.81 to 0.95) 25.33 (23.27 to 27.57) 28.85 (27.93 to 29.81)
Outpatient‡ 1.03 (0.79 to 1.33) 25.12 (19.36 to 32.59) 24.47 (22.33 to 26.81)
Inability to work (sick leave days)§ 2.40† (1.52 to 3.81) 34.64 (22.05 to 54.44) 14.41 (13.26 to 15.66)
GEE models with a γ distribution and a log link based on 9160 observations from 6803 participants.
Models are adjusted for age, sex and educational level and accounted for the repeated measurement structure.
*Exponentiated estimate, non-diabetic participants as reference group.
†Significant at the level of 1%.
‡In total,1909 observations were omitted in the model due to missing information in Age1, Age2.
§Only for observations <65 years with a regular job (n=3637 observations).
GP, general practitioner.
Table 4 Annual direct and indirect per capita costs
Type 2 diabetes No diabetes
Ratio* (95% CI) Adjusted means (95% CI) Adjusted means (95% CI)
Direct costs 1.81† (1.56 to 2.11) 3352 (2899 to 3877) 1849 (1741 to 1964)
Physician visits
GPs 1.57† (1.42 to 1.75) 136 (123 to 151) 87 (83 to 90)
Specialists 2.14† (1.41 to 3.25) 91 (60 to 136) 42 (38 to 48)
Others 1.36† (1.17 to 1.57) 213 (185 to 244) 157 (149 to 165)
Total 1.53† (1.36 to 1.73) 445 (396 to 500) 290 (279 to 303)
Hospital
Inpatient 1.82† (1.43 to 2.31) 1664 (1320 to 2098) 917 (830 to 1013)
Outpatient 0.89 (0.68 to 1.17) 19 (15 to 24) 21 (19 to 24)
Rehabilitation
Inpatient 1.80† (1.42 to 2.3) 181 (142 to 230) 100 (89 to 113)
Outpatient 0.68 (0.45 to 1.02) 14 (10 to 21) 21 (18 to 24)
Medication 2.01† (1.78 to 2.26) 960 (856 to 1076) 478 (439 to 521)
Indirect costs‡ 2.07† (1.51 to 2.84) 4103 (3024 to 5567) 1981 (1800 to 2180)
Inability to work§ (sick leave days) 2.57† (1.52 to 4.36) 3344 (1995 to 5607) 1299 (1185 to 1423)
GEE models with a γ distribution and a log link. Models based on 9160 observations from 6803 participants. €1 was assigned to observations
with zero costs.
Models are adjusted for age, sex and educational level and accounted for the repeated measurement structure.
*Exponentiated estimate, non-diabetic participants as reference group.
†Significant at the level of 1%.
‡Only for observations <65 years (n=5207 observations).
§Only for observations <65 years with a regular job (n=3637 observations).
GP general practitioner.
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Calculating medication costs on the basis of the DDD
instead of participants’ information affected the cost esti-
mates only marginally. When the friction cost approach
for calculating indirect costs was applied, absolute indir-
ect costs were 20% lower than those estimated with the
human capital approach. However, the relative differ-
ence between the diabetic and non-diabetic group
regarding indirect costs did not differ.
DISCUSSION
Detailed knowledge about the cost of chronic diseases is
needed for resource allocation and decision-making in
healthcare. This survey-based bottom-up study examines
the association between type 2 diabetes and healthcare
usage, productivity losses and associated direct and indir-
ect costs in Germany based on data from over 6000 par-
ticipants. We found that adjusted direct and indirect
costs of participants with type 2 diabetes were roughly
two times and three times higher than the costs of those
without type 2 diabetes. The finding for direct costs was
mainly driven by costs for inpatient hospital treatments
and medication. Furthermore, we observed a significant
increase in direct costs among patients with cardiovascu-
lar complications, long diabetes duration and therapy
with insulin.
The results of this study show that individuals with dia-
betes were more likely to use healthcare than those
without diabetes, and that if having used resources, the
magnitude of usage was in general higher, resulting in
1.8 times higher direct costs. Previous cost-of-illness
studies in Germany largely relied on administrative
claims data from health insurance companies. The Costs
of Diabetes Mellitus (CoDiM) study, the largest claims
data-based study, indicated that in 2010 direct medical
costs for patients with and without diabetes were €5084
and €2693, respectively.36 Whereas the absolute mean
costs in our study were substantially lower (€3352 vs
€1849), the cost ratio between patients with and without
diabetes was quite comparable to that of the CoDiM
study (1.8 in this study vs 1.9 in CoDiM). Several reasons
might have contributed to these differences in total
mean costs for diabetes. First, the CoDiM studies com-
prised cost components that were not incorporated in
our analyses, such as medical devices, home care, trans-
portation and other remedies covered by the AOK
health insurance, and previous research has shown that
self-reports on resource usage from surveys tend to
underestimate the absolute costs.7 36 37 Second, severely
ill patients or participants close to death with and
without diabetes with very high costs are unlikely to par-
ticipate in population-based survey studies such as
KORA, but are included in insurance claims data
leading to an underestimation of costs with the chosen
approach. Third, higher absolute costs in CoDiM might
be partially related to the membership structure of the
AOK, which is known to have members with higher risk





Type 2 diabetes without cardiovascular complications 1.54‡ (1.30 to 1.82)
Type 2 diabetes with cardiovascular complications 2.77‡ (2.12 to 3.61)
Type of treatment
Type 2 diabetes without pharmacological treatment 1.26 (0.93 to 1.72)
Type 2 diabetes with OAD only 1.53‡ (1.25 to 1.88)
Type 2 diabetes with OAD and insulin 2.58‡ (1.90 to 3.50)
Type 2 diabetes with insulin only 3.98‡ (2.74 to 5.77)
Glycaemic control
Type 2 diabetes with HbA1c<6.5% 1.87‡ (1.51 to 2.32)
Type 2 diabetes with 6.5%≤HbA1c<7.5% 1.64‡ (1.33 to 2.03)
Type 2 diabetes with 7.5%≤HbA1c<9.0% 1.94‡ (1.44 to 2.62)
Type 2 diabetes with HbA1c≥9.0% 2.24‡ (1.34 to 3.73)
Diabetes duration
Type 2 diabetes: 0–2 years 1.90‡ (1.24 to 2.62)
Type 2 diabetes: 3–10 years 1.44‡ (1.19 to 1.74)
Type 2 diabetes: 11–19 years 2.21‡ (1.58 to 3.10)
Type 2 diabetes:≥20 years 3.02‡ (2.17 to 4.22)
GEE models with a γ distribution and a log link. Models based on 9160 observations from 6803 participants.
Models are adjusted for age, sex and educational level and accounted for the repeated measurement structure.
*€ was assigned to observations with zero costs.
†Exponentiated estimate, non-diabetic participants as reference group.
‡Significant at the level of 1%.
OAD, oral antidiabetic drugs.
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and lower socioeconomic status than the general
German population.38
The results of our analyses are also in line with evi-
dence from the international literature. Studies from
Europe and North America showed that medical expen-
ditures for people with diabetes are around 1.7 times
(Spain), 4.0 times (Italy), 2.5 times (Canada) and
2.3 times (USA) higher than for people without
diabetes.14–16 18
This study is one of the first that adjusted the cost
models for weight status, a factor that very often pre-
cedes the onset of type 2 diabetes. Estimating the excess
costs of diabetes conditional on BMI allows quantifying
the burden of diabetes on healthcare systems independ-
ent from the weight status. Results show that excess costs
ratios decreased only marginally, indicating that diabetes
and not obesity is the driving factor for increased health-
care costs in patients with diabetes.
We could show that inpatient care and medication
constitute the largest part of medical costs. In addition,
health care costs of individuals with diabetes and cardio-
vascular complications were two times higher than those
of individuals with diabetes but without cardiovascular
complications and almost three times higher than those
of individuals without diabetes. The former finding con-
firms results from previous studies which also found that
inpatient care and medication were the biggest cost
drivers.7 12 13 39 The latter finding is also supported by
data from the CoDiM study which provided a cost ratio of
about 3.1 for patients with diabetes with stroke and about
2.6 for patients with myocardial infarction compared with
those without diabetes,36 indicating that a large share of
the costs for diabetes is attributable to the treatment of
diabetes-related complications.20 24 We also observed that
the type of treatment had a strong effect on direct costs.
In our study, patients with type 2 diabetes with insulin
monotherapy or with a combination of insulin and oral
antidiabetic drugs had significantly elevated costs com-
pared with individuals without diabetes (3.98 and 2.58,
respectively). The CoDiM study identified similar cost
ratios of 3.4 and 3.1, respectively.7 As found in a big US
study, the association between diabetes duration and
direct costs followed an inverse U-shaped curve with
highest excess costs for a diabetes duration of <2, 10–20
and >20 years and lower costs for patients with a diabetes
duration of 3–10 years.40
To the best of our knowledge, our study is the first
large German study to examine the impact of glycaemic
control and diabetes duration on direct medical costs.
As in previous international studies which have shown
that good glycaemic control is associated with at least a
small cost reduction, we found that good glycaemic
control was weakly, non-significantly associated with
direct medical costs.41 42 It is worth mentioning that
after mutual adjustment for cardiovascular complica-
tions, diabetes duration, glycaemic control and type of
treatment, only the factors cardiovascular complications
and type of treatment were significantly associated with
direct costs. This indicates multicollinearity between
these factors and highlights that specifically the disease
severity and not the duration or glycaemic control is the
crucial driver of direct medical costs.
Besides having higher direct costs, patients with dia-
betes had substantially more sick leave days and were
more likely to receive incapacity benefits due to early
retirement, resulting in 2.07 times higher indirect costs
(€4103 vs €1981). With this, absolute indirect excess
costs exceed absolute direct excess costs, highlighting
the indirect cost burden of type 2 diabetes. The costs for
sick leave days were substantially higher than those from
the CoDiM study, although similar unit costs were
applied for productivity losses (€764 vs €576, factor 1.3
in CoDiM compared with €3344 vs €1299, factor 2.57 in
this study). The reason for this discrepancy is unknown,
but might be related to the incomplete documentation
of sick leave days in routine claims data. Owing to spe-
cific characteristics of documentation, sick leave periods
with a period of <4 days appear only fragmentary in
claims data of statutory health insurance companies.
One of the strengths of our study is the population-
based data source with more than 9000 observations. A
further advantage is the detailed analysis of direct and
indirect costs on the basis of self-reported healthcare
usage and loss of productivity. Former studies mostly
focused on direct costs and recent evidence on indirect
costs is especially scarce. Although the validity of self-
reported information on productivity losses is unknown,
it should be mentioned that the reported number of
sick leave days of people with work in the sample
(8 days) is quite similar to the number of sick leave days
published by the Research Institute of the Federal
Employment Agency for the years 2007–2013 (8.1–
9.5 days). Another strength of the study is that we
excluded patients with type 1 diabetes from the analysis
and examined important diabetes-related factors such as
glycaemic control and diabetes duration that cannot be
analysed with administrative claims data.
Several limitations of our study must be noted. Only
participants from the region of Augsburg were sampled
and elderly people were over-represented in the sample
as the Age1 and Age2 surveys comprised only individuals
aged ≥65 and ≥68 years, respectively. Furthermore, for
example, the S4 survey had a response of 66% and the
response to its follow-up, the F4 survey, in turn was 80%.
Also, severely ill individuals might not be included in
our study because of their inability to get interviewed in
the KORA study centre. These issues limit the generalis-
ability of results for the German population.
Furthermore, not all components of resource usage asso-
ciated with healthcare costs could be assessed and all
information on healthcare usage and productivity losses
was based on self-reports. In addition, healthcare usage
and productivity losses were priced with an average refer-
ence value, which might deviate from the actual costs.
This could under estimate health care costs, as it is
known that healthcare use, for example, a GP visit or
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hospitalisation due to diabetic complications or cardio-
vascular interventions such as angiographies or stents
are more costly than ‘average’ GP contacts or hospitalisa-
tions and second more likely to occur in people with
diabetes.43 Since individual resource consumption and
productivity losses were recorded retrospectively within a
period of 3–12 months, recall bias is likely to have
occurred. The problem of recall bias and missing cost
components might have led to an underestimation of
absolute costs; however, its effect on relative excess cost
estimates is expected to be rather small.37 44 Limited
information on other diabetic complications such as
heart failure or microvascular complications also pre-
vented a more detailed analysis of underlying cost
drivers. Finally, incomplete balancing of participant
characteristics with the used regression approach and
residual confounding due to factors which were not
adjusted for in the regression models could have biased
the effect estimates in either direction.
In conclusion, our results underline the societal cost
burden of diabetes. In particular, indirect costs which
appeared to be higher than the direct costs should
be considered when quantifying the cost burden of
diabetes and other chronic diseases. Since the excess
costs were largely attributable to complications and
severity of the disease, strong effort is required to
optimise care to avoid progression of the disease and
costly complications.
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